JP2014506259A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506259A5
JP2014506259A5 JP2013548861A JP2013548861A JP2014506259A5 JP 2014506259 A5 JP2014506259 A5 JP 2014506259A5 JP 2013548861 A JP2013548861 A JP 2013548861A JP 2013548861 A JP2013548861 A JP 2013548861A JP 2014506259 A5 JP2014506259 A5 JP 2014506259A5
Authority
JP
Japan
Prior art keywords
seq
cdr
ligand
antibody
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013548861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506259A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/050633 external-priority patent/WO2012098113A1/en
Publication of JP2014506259A publication Critical patent/JP2014506259A/ja
Publication of JP2014506259A5 publication Critical patent/JP2014506259A5/ja
Withdrawn legal-status Critical Current

Links

JP2013548861A 2011-01-17 2012-01-17 Il−21リガンド Withdrawn JP2014506259A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP11151073 2011-01-17
EP11151073.1 2011-01-17
US201161434989P 2011-01-21 2011-01-21
US61/434,989 2011-01-21
EP11168328 2011-05-31
EP11168328.0 2011-05-31
US201161493002P 2011-06-03 2011-06-03
US61/493,002 2011-06-03
EP11187212.3 2011-10-31
EP11187212 2011-10-31
PCT/EP2012/050633 WO2012098113A1 (en) 2011-01-17 2012-01-17 Il-21 ligands

Publications (2)

Publication Number Publication Date
JP2014506259A JP2014506259A (ja) 2014-03-13
JP2014506259A5 true JP2014506259A5 (enExample) 2015-03-05

Family

ID=46515179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013548861A Withdrawn JP2014506259A (ja) 2011-01-17 2012-01-17 Il−21リガンド

Country Status (5)

Country Link
US (1) US20130323259A1 (enExample)
EP (1) EP2665750A1 (enExample)
JP (1) JP2014506259A (enExample)
CN (1) CN103443124A (enExample)
WO (1) WO2012098113A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1963369B1 (en) 2005-11-28 2013-05-15 Zymogenetics, Inc. Il-21 antagonists
EP2746292A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of nephropathies
EP2746293A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of cardiovascular diseases
JP2017507132A (ja) * 2014-02-07 2017-03-16 ノヴォ ノルディスク アー/エス 抗体プロセス
AR099625A1 (es) 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
JP6672175B2 (ja) * 2014-05-07 2020-03-25 ノヴォ ノルディスク アー/エス Glp−1及び抗il−21を使用した1型糖尿病の治療
SMT201900668T1 (it) 2014-06-06 2020-01-14 Bristol Myers Squibb Co Anticorpi contro il recettore per il fattore di necrosi tumorale indotto da glucocorticoidi(gitr)e loro usi
EP3304079B1 (en) 2015-06-03 2020-06-03 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
KR20180082563A (ko) 2015-11-19 2018-07-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380958T3 (es) 1999-12-23 2012-05-21 Genentech, Inc. Polipéptidos homólogos IL-17 y utilizaciones terapéuticas de los mismos
SG177012A1 (en) * 2002-05-20 2012-01-30 Abmaxis Inc Generation and selection of protein library in silico
CN101014364B (zh) * 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
EP1963369B1 (en) * 2005-11-28 2013-05-15 Zymogenetics, Inc. Il-21 antagonists
CA2633138A1 (en) * 2005-12-23 2007-06-28 Viventia Biotech Inc. Methods for generating and screening fusion protein libraries and uses thereof
WO2009047360A1 (en) * 2007-10-11 2009-04-16 Novo Nordisk A/S Il-21 antibodies
BRPI0821168B8 (pt) * 2007-12-07 2021-05-25 Zymogenetics Inc anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
WO2009132821A1 (en) * 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
WO2010027981A1 (en) * 2008-09-03 2010-03-11 Genentech, Inc. Multispecific antibodies
SG175396A1 (en) * 2009-04-29 2011-12-29 Centocor Ortho Biotech Inc Toll-like receptor 3 antagonists

Similar Documents

Publication Publication Date Title
JP2014506259A5 (enExample)
JP2014205674A5 (enExample)
JP2019528240A5 (enExample)
JP2014526898A5 (enExample)
HRP20210170T1 (hr) Protutijela protiv b7-h3 i konjugati protutijela s lijekom
HRP20211343T1 (hr) Protutijela protiv dkk-1
JP2016196468A5 (enExample)
JP2015532292A5 (enExample)
JP2016502515A5 (enExample)
JP2018507220A5 (enExample)
NZ608206A (en) Antibodies that bind myostatin, compositions and methods
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
JP2018508483A5 (enExample)
JP2011046732A5 (enExample)
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
JP2015514110A5 (enExample)
ME02533B (me) BISPECIFIČNA ANTITELA PROTIV CD3-EPSILON l BCMA
JP2020502996A5 (enExample)
JP2016538830A5 (enExample)
JP2013538057A5 (enExample)
JP2015502138A5 (enExample)
JP2014502955A5 (enExample)
RU2016129517A (ru) Биспецифические антитела к her2 и способы применения
JP2016512551A5 (enExample)